Research groups

GC04 Inflammation and Cancer

The Group’s main areas of research over recent years are the identification of the molecular signaling pathways that regulate inflammation processes and tumorigenesis, and the latency of HIV-1. The identification of the molecular targets that regulate these processes helps us identify new natural compounds and derivatives (drugs and nutraceuticals) inhibiting the activity of these targets.

Our research studies have allowed us to establish sophisticated models of biological activity screening in molecules with therapeutic potential and collaborate with many leading international research groups in the field of pharmaceutical Chemistry. We recently established a new research area focused on the study of the inflammatory processes that occur in skin ulcers, to develop new formulations based on biopharmaceuticals and natural products favouring tissue regeneration.

Research Lines

Networks

    AIDS Research Network (RIS)

    PAIDI BIO-304 scientific group

Keywords

  • Inflammation
  • cancer
  • tissue regeneration
  • HIV-1 latency
  • Pharmacology and Nutraceuticals.

GC04 Inflammation and Cancer

Principal Investigator
Eduardo Muñoz Blanco

Co-Principal Investigator
Marco Antonio Calzado Canale

Post-Doctoral Researchers
Carmen Navarrete Rueda
Jon Peñarando Sáez

Pre-Doctoral Researchers
Martín Garrido Rodríguez-Córdoba
Estrella Millán Ortega
María Eugenia Prados González
Rosario Morrugares Carmona
Belén Palomares Cañero
Alejandro Correa Sáez
Rafael Jiménez Izquierdo

Technical and Administrative Staff
Juan Antonio Collado Rojas
Ana María Mellado Fuentes

Projects

Active Projects

National

Muñoz Blanco, E. Study of the mechanism of action of vce-004.8, a cannabidiol quinone derivative. Therapeutic implications in multiple sclerosis. Funding agency: Spanish Ministry of Economy and Competitiveness (MINECO). Reference:  SAF2017-87701-R R

MUÑOZ BLANCO, EDUARDO/ CALZADO CANALE, MARCO A; Desarrollo preclínico de nuevos triterpenos hydroxamatos. MINISTERIO DE ECONOMIA Y EMPRESA; Reference: RTC-2017-6109-1

Publications

Main Publications 2019

Morrugares R, Correa-Sáez A, Moreno R, Garrido-Rodríguez M, Muñoz E, de la Vega L, Calzado MA. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2. Cell Mol Life Sci. 2019 Oct 11. doi: 10.1007/s00018-019-03309-9
IF: 7,014
D: 1

García-Martín A, Garrido-Rodríguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, Rolland A, Appendino G, Muñoz E. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis. Biochem Pharmacol. 2019 May; 163:321-334. doi: 10.1016/j.bcp.2019.02.029.
IF: 4,825
D: 1

Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. LUBAC determines chemotherapy resistance in squamous cell lung cancer. J Exp Med. 2019 Feb 4;216(2):450-465. doi: 10.1084/jem.20180742
IF: 10,892
D: 1

Garrido-Rodríguez M, Ortea I, Calzado MA, Muñoz E, García V. SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. J Proteomics. 2019 Feb 20; 193:217-229. doi: 10.1016/j.jprot.2018.10.012.
IF: 3, 537
Q: 1

Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E, Galve-Roperh I. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-inducedneurodegeneration. Transl Neurodegener. 2019 Mar 8;8:9. doi:10.1186/s40035-019-0148-x
IF: 5,534
Q: 1

Main Publications 2018

Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. LUBAC determines chemotherapy resistance in squamous cell lung cancer. J Exp Med. 2019 Feb 4;216(2):450-465.
IF: 10.892
Q: 1  D: 1

Minassi A, Rogati F, Cruz C, Prados ME, Galera N, Jinenez C, Appendino G, Bellido ML, Calzado MA, Caprioglio D, Munoz E. Triterpenoid Hydroxamates as HIF Prolyl Hydrolase Inhibitors. JOURNAL OF NATURAL PRODUCTS. 2018; 81(10):2235-2243.
IF: 3,885  
Q: 1   D: 1

Moreno P, Jimenez-Jimenez C, Garrido-Rodriguez M, Calderon-Santiago M, Molina S, Lara-Chica M, Priego-Capote F, Salvatierra A, Munoz E, Calzado MA. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. MOLECULAR ONCOLOGY. 2018; 12(10):1778-1796.
IF: 5,264  
Q: 1

del Rio C, Cantarero I, Palomares B, Gomez-Canas M, Fernandez-Ruiz J, Pavicic C, Garcia-Martin A, Bellido ML, Ortega-Castro R, Perez-Sanchez C, Lopez-Pedrera C, Appendino G, Calzado MA, Munoz E. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR gamma- and CB2 receptor-dependent pathways. BRITISH JOURNAL OF PHARMACOLOGY. 2018. 175(19):3813-3831.
IF: 6,81  
Q: 1   D: 1

Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jimenez-Jimenez C, Mestre L, Feliu A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Munoz E. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. JOURNAL OF NEUROINFLAMMATION. 2018; 15:Núm artículo 64
IF: 5,193  
Q: 1

Other Publications 2018

Jimenez-Jimenez C, Lara-Chica M, Palomares B, Collado JA, Lopez-Mirand J, Munoz E, Calzado MA. Effect of N-acyl-dopamines on beta cell differentiation and wound healing in diabetic mice. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. 2018; 1865(11):1539-1551.
IF: 4,651  
Q: 1

Garcia-Martin A, Garrido-Rodriguez M, Navarrete C, del Rio C, Bellido ML, Appendino G, Calzado MA, Munoz E. EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. BIOCHEMICAL PHARMACOLOGY. 2018; 157:304-313.
IF: 4,235  
Q: 1

del Rio C, Millan E, Garcia V, Appendino G, DeMesa J, Munoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. BIOCHEMICAL PHARMACOLOGY. 2018; 157:122-133.
IF: 4,235  
Q: 1

Palomares B, Ruiz-Pino F, Navarrete C, Velasco I, Sanchez-Garrido MA, Jimenez-Jimenez C, Pavicic C, Vazquez MJ, Appendino G, Bellido ML, Calzado MA, Tena-Sempere M, Munoz E. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. SCIENTIFIC REPORTS. 2018; 8:Núm artículo 16092
IF: 4,122  
Q: 1

Garcia C, Gomez-Canas M, Burgaz S, Palomares B, Gomez-Galvez Y, Palomo-Garo C, Campo S, Ferrer-Hernandez J, Pavicic C, Navarrete C, Bellido ML, Garcia-Arencibia M, Pazos MR, Munoz E, Fernandez-Ruiz J. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR gamma receptor. JOURNAL OF NEUROINFLAMMATION. 2018; 15:Núm artículo 19
IF: 5,193  
Q: 1

Nizet S, Munoz E, Fiebich BL, Abuja PM, Kashofer K, Zatloukal K, Tangermann S, Kenner L, Tschegg C, Nagl D, Scheichl L, Meisslitzer-Ruppitsch C, Freissmuth M, Berger T. Clinoptilolite in Dextran Sulphate Sodium-Induced Murine Colitis: Efficacy and Safety of a Microparticulate Preparation. INFLAMMATORY BOWEL DISEASES. 2018; 24(1):54-66.
IF: 4,347  
Q: 1

Rodriguez-Cueto C, Santos-Garcia I, Garcia-Toscano L, Espejo-Porras F, Bellido M, Fernandez-Ruiz J, Munoz E, de Lago E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1(G93A) transgenic mice, an experimental model of amyotrophic lateral sclerosis. BIOCHEMICAL PHARMACOLOGY. 2018; 157:217-226.
IF: 4,235  
Q: 1

Luesma MJ, Cantarero I, Castiella T, Sanchez-Cano AI, Iruzubieta P, Junquera C. Ultrastructural and immunohistochemical study of phenotypic switch in gastrointestinal smooth muscle cells. MICROSCOPY RESEARCH AND TECHNIQUE. 2018; 81(11):1233-1240.
IF: 1,087  
Q: 3

Pollastro F, Caprioglio D, Del Prete D, Rogati F, Minassi A, Taglialatela-Scafati O, Munoz E, Appendino G. Cannabichromene. NATURAL PRODUCT COMMUNICATIONS. 2018;  3(9):1189-1194.
IF: 8,9  
Q: 4

Appel K, Munoz E, Navarrete C, Cruz-Teno C, Biller A, Thiemann E. Immunomodulatory and Inhibitory Effect of Immulina (R), and Immunloges (R) in the Ig-E Mediated Activation of RBL-2H3 Cells. A New Role in Allergic Inflammatory Responses. PLANTS-BASEL. 2018; 7(1):Núm artículo 13
IF: 0

Main Publications 2017

Nadal X, del Rio C, Casano S, Palomares B, Ferreiro-Vera C, Navarrete C, Sanchez-Carnerero C, Cantarero I, Bellido ML, Meyer S, Morello G, Appendino G, Munoz E. Tetrahydrocannabinolic acid is a potent PPAR gamma agonist with neuroprotective activity. BRITISH JOURNAL OF PHARMACOLOGY. 2017.174(23):4263-4276.
IF: 5,491
Q: 1  D: 1

Other Publications 2017

Saliba SW, Marcotegui AR, Fortwangler E, Ditrich J, Perazzo JC, Munoz E, de Oliveira ACP, Fiebich BL. AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity. JOURNAL OF NEUROINFLAMMATION. 2017. 14(1):246.
IF:  5,102
Q: 1

Nizet S, Muñoz E, Fiebich BL, Abuja PM, Kashofer K, Zatloukal K, Tangermann S, Kenner L, Tschegg C, Nagl D, Scheichl L, Meisslitzer-Ruppitsch C, Freissmuth M, Berger T. Clinoptilolite in Dextran Sulphate Sodium-Induced Murine Colitis: Efficacy and Safety of a Microparticulate Preparation. INFLAMMATORY BOWEL DISEASES. 2017. 24(1):54-66.
IF: 4,525
Q: 1 

Gomez-Canas M, Morales P, Garcia-Toscano L, Navarrete C, Munoz E, Jagerovic N, Fernandez-Ruiz J, Garcia-Arencibia M, Pazos MR. Corrigendum to "Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile" [Pharmacol. Res. 110 (August 2016) (2016) 205-215]. PHARMACOLOGICAL RESEARCH. 2017.120:302.
IF: 4,48
Q: 1 

Del Prete D, Taglialatela-Scafati O, Minassi A, Sirignano C, Cruz C, Bellido ML, Munoz E, Appendino G. Electrophilic Triterpenoid Enones: A Comparative Thiol-Trapping and Bioactivity Study. JOURNAL OF NATURAL PRODUCTS. 2017.80(8):2276-2283.
IF: 3,281
Q: 1  

Egas V, Millan E, Collado JA, Ramirez-Apan T, Mendez-Cuesta CA, Munoz E, Delgado G. Effect of natural and semi-synthetic cadinanes from Heterotheca inuloides on NF-kappa B, Nrf2 and STAT3 signaling pathways and evaluation of their in vitro cytotoxicity in human cancer cell lines. BIOORGANIC & MEDICINAL CHEMISTRY. 2017.25(12):3135-3147.
IF: 2,93
Q: 2 

Olmedo DA, Lopez-Perez JL, del Olmo E, Bedoya LM, Sancho R, Alcami J, Munoz E, San Feliciano A, Gupta MP. Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-B Pathways. MOLECULES. 2017.22(2):-E321.
IF: 2,861
Q: 2 

Formisano C, Sanna C, Ballero M, Chianese G, Sirignano C, Rigano D, Millan E, Munoz E, Taglialatela-Scafati O. Anti-inflammatory sesquiterpene lactones from Onopordum illyricum L. (Asteraceae), an Italian medicinal plant.  FITOTERAPIA. 2017.116:61-65.
IF: 2,698
Q: 2 

Members

Dr. Eduardo Muñoz Blanco

Principal Investigator

Marco Antonio Calzado Canale

Co-Principal Investigator

Team

Carmen Navarrete Rueda, Jon Peñarando Sáez, Martín Garrido Rodríguez-Córdoba, Estrella Millán Ortega, María Eugenia Prados González, Rosario Morrugares Carmona, Belén Palomares Cañero, Alejandro Correa Sáez, Rafael Jiménez Izquierdo, Juan Antonio Collado Rojas, Ana María Mellado Fuentes